The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.

Driscoll, J; Pelluru, D; Lefkimmiatis, K; Fulciniti, M; Prabhala, R; Greipp, P; Barlogie, B; Tai, Y; Anderson, K; Shaughnessy, J; Annunziata, C; Munshi, N

Journal article

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.

Abstract:: Multiple myeloma (MM) is a plasma cell neoplasm that proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however, the molecular events responsible for myelomagenesis remain uncharacterized. To identify cellular pathways deregulated in MM, we addressed that sumoylation is homologous to ubiquitination and results in the attachment of the ubiquitin-like protein Sumo onto target proteins. Sumoylation was markedly enhanced in MM patient lysates compared with normal plasma cells and expression profiling indicated a relative induction of sumoylation pathway genes. The Sumo-conjugating enzyme Ube2I, the Sumo-ligase PIAS1, and the Sumo-inducer ARF were elevated in MM patient samples and cell lines. Survival correlated with expression because 80% of patients with low UBE2I and PIAS1 were living 6 years after transplantation, whereas only 45% of patients with high expression survived 6 years. UBE2I encodes the sole Sumo-conjugating enzyme in mammalian cells and cells transfected with a dominant-negative sumoylation-deficient UBE2I mutant exhibited decreased survival after radiation exposure, impaired adhesion to bone marrow stroma cell and decreased bone marrow stroma cell-induced proliferation. UBE2I confers cells with multiple advantages to promote tumorigenesis and predicts decreased survival when combined with PIAS1. The sumoylation pathway is a novel therapeutic target with implications for existing proteasomal-based treatment strategies.

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Driscoll, J., Pelluru, D., Lefkimmiatis, K., Fulciniti, M., Prabhala, R., Greipp, P., Barlogie, B., Tai, Y., Anderson, K., Shaughnessy, J., Annunziata, C., & Munshi, N. (2010). The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood, 115(14), 2827–2834.

MLA Style

Driscoll, J., et al. “The Sumoylation Pathway Is Dysregulated in Multiple Myeloma and Is Associated with Adverse Patient Outcome.” Blood, vol. 115, no. 14, 2010, pp. 2827–34.

Chicago Style

Driscoll, J, D Pelluru, K Lefkimmiatis, M Fulciniti, R Prabhala, P Greipp, B Barlogie, et al. 2010. “The Sumoylation Pathway Is Dysregulated in Multiple Myeloma and Is Associated with Adverse Patient Outcome.” Blood 115 (14): 2827–34.
Share
Print